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Background: We evaluated quality of life among subjects with upper- and lower-limb spasticity who received
escalating doses of incobotulinumtoxinA (total body doses up to 800 U) in the prospective, single-arm,
dose-titration TOWER study.
Methods: In this exploratory trial, subjects (N = 155; 18–80 years of age) with upper- and lower-limb spasticity due
to cerebral causes who were deemed to require total body doses of up to 800 U incobotulinumtoxinA received
three consecutive injection cycles of incobotulinumtoxinA (400, 600, and up to 800 U), each with 12 to 16 weeks’
follow-up. QoL was assessed using the EuroQol 5-dimensions questionnaire, three-level (EQ-5D), before and 4 weeks
post-injection in each injection cycle and at the end of injection cycle 3.
Results: The mean EQ-5D visual analog scale scores of 155 participants continuously improved from study baseline
to 4 weeks post-injection in all injection cycles (mean [standard deviation] change 6.7 [14.1], 9.6 [16.3], and 8.6 [17.0]
for injection cycles 1, 2, and 3, respectively; p < 0.0001 for all, paired sample t-test). In general, among those with a
change in the EQ-5D rating of their condition, the proportion of subjects with ‘improvement’ was greater than that
with ‘worsening’ for individual EQ-5D dimensions across all injection cycles. At the end of injection cycle 3, the
proportion of subjects rating their condition as ‘normal’ increased from study baseline for all dimensions, and there
was a ≥ 46% reduction in the proportion of subjects with a rating of ‘severe impairment’.
Conclusion: These preliminary results suggest that escalating incobotulinumtoxinA doses up to 800 U are
associated with improvement in quality of life ratings in subjects with multifocal upper- and lower-limb spasticity,
and form a basis for future comparator studies.
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Disabling spasticity of the upper and lower limbs is a
common and often painful complication of stroke and
results in marked limitations of subjects’ mobility and
their ability to perform routine daily tasks, such as dress-
ing and personal hygiene [1–5]. These effects have an
impact on subjects’ quality of life (QoL), with many sub-
jects reporting dependence on family and carers, social
isolation, and depression [1, 2, 6, 7]. Improvement in
QoL is often a key goal for subjects with spasticity [1];
QoL measures should therefore play a vital role in the
assessment of clinical interventions.
Botulinum neurotoxin type A (BoNT-A) formulations
are recommended in general spasticity guidelines for the
treatment of focal spasticity of the upper and lower
limbs [8, 9]. The efficacy and safety of treatment with
BoNT-A formulations in subjects with focal spasticity
are well established [10–19]. However, treating multi-
focal upper- or lower-limb spasticity may require total
doses of BoNT-A higher than those currently approved,
in order to meet subjects’ clinical needs and goals of
rehabilitation therapy [20].
Previous data have indicated the immunologic and
toxicologic safety of incobotulinumtoxinA doses up to
1200 mouse units in subjects with spasticity or dystonia
[21]. Recommendations of incobotulinumtoxinA for
upper-limb spasticity include ≤400 U per session in the
United States and ≤ 500 U per session in the European
Union, no more frequently than every 12 weeks [22, 23].
The prospective, single-arm, dose-titration TOWER
study was designed to assess the safety and efficacy of
escalating incobotulinumtoxinA doses (total body doses
of 400 U, 600 U, and up to 800 U) in adults with multi-
focal spasticity of the upper and lower limbs, on the
same body side, as a result of stroke or other cerebral
causes [20]. With regards to safety, the incidence of
treatment-related adverse events did not increase with
escalating incobotulinumtoxinA doses up to 800 U. Dose
escalation improved muscle tone, with mean improve-
ments in Resistance to Passive Movement Scale
(REPAS) [24] scores at 4 weeks post-injection of − 4.6,
− 5.9, and − 7.1 for consecutive injection cycles with
400 U, 600 U, and up to 800 U, respectively (all
p < 0.0001, Student’s t-test for paired samples) [20].
While the safety and efficacy of BoNT-A treatments are
well reported, data on subjects’ QoL following BoNT-A
treatment remain limited and largely inconclusive [1, 3,
25], with extremely limited data available to date on QoL
following combined treatment of upper-and lower-limb
spasticity [1]. Furthermore, few studies report baseline
scores for QoL in untreated subjects with spasticity [3, 4],
leading to a lack of normative data for comparison. In
order to address this knowledge gap and to better under-
stand the effects of escalating incobotulinumtoxinAtreatment on subjects’ QoL, we report QoL outcomes
based on the EuroQol 5-dimensions questionnaire, three-
level (EQ-5D) [26, 27], following incobotulinumtoxinA




TOWER (The Titration study in lOWer and uppER limb
spasticity; NCT01603459) was a prospective, single-arm,
multicenter, non-randomized dose-titration study investi-
gating the safety and efficacy of incobotulinumtoxinA in
subjects with upper- and lower-limb spasticity who were
deemed by the investigator to require total body doses of
800 U incobotulinumtoxinA. The study was conducted at
30 centers in Europe and North America. To minimize
potential bias of subject-rated outcomes, subjects were
blinded to which dose they were receiving during which
cycle. Study details, safety and results from selected effi-
cacy variables have been published elsewhere [20].
In brief, the study comprised three consecutive, flex-
ible, 12–16-week injection cycles, in which the following
escalating doses of incobotulinumtoxinA (BoNT-A free
from complexing proteins, Xeomin®, Merz Pharmaceuti-
cals GmbH) were administered by intramuscular injec-
tion in the same body side on the first day of each
injection cycle: cycle 1, a fixed total body dose of 400 U
into the upper limb or lower limb only, or split between
both; cycle 2, a fixed total body dose of 600 U into the
upper limb or lower limb only, or split between both;
cycle 3, a total body dose of 800 U split between both
upper and lower limbs (maximum dose of 600 U per
limb) or a lower total dose of between 600 and 800 U, if
800 U was not indicated for clinical or safety reasons.
The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. The protocol was
approved by the local institutional review boards and
independent ethics committees.
Subjects
Subjects eligible to participate in the study were male or
female and 18–80 years of age with chronic (≥ 12 weeks
since the last event leading to spasticity on the side of
the body with the selected target clinical pattern diag-
nosed by a healthcare professional) upper- and lower-
limb spasticity of the same body side due to cerebral
causes, and were considered by the investigator to
require total body doses of 800 U incobotulinumtoxinA
during the course of the study. Subjects with bilateral
symptoms due to cerebral or brainstem lesions were
eligible if they agreed to be treated on only one side of
the body. The area of the target clinical pattern selected
for treatment was required to have an Ashworth Scale
score ≥ 2 and a Disability Assessment Scale (DAS)
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included: spinal lesions; neurological conditions associated
with neuromuscular dysfunction; fixed contracture or
muscle hypertonia other than spasticity in the joint associ-
ated with the selected target clinical pattern; severe atrophy
of muscles associated with the target clinical pattern; prior
or planned surgery of the target limb (within 8 weeks) or
muscle; treatment with intrathecal baclofen or antispasti-
city medication with peripheral muscle relaxants within 2
weeks prior to screening; change in antidepressant medica-
tion within 4 weeks prior to screening or within the screen-
ing period; change in antispastic medication with centrally
acting muscle relaxants within 2 weeks prior to screening
or within the screening period; infection of planned injec-
tion sites; generalized muscle disorders or any other per-
ipheral neuromuscular dysfunction; rheumatic disease in
the limbs of the targeted body side; adverse reaction of
severe intensity to BoNT-A or BoNT-B lasting > 1 week
within previous 12months; international normalized ratio
(INR) value > 1.5 and/or a partial thromboplastin time
value of > 1.5-times the upper limit of normal; and forced
expiratory volume in 1 s (FEV1) < 70%. Eligibility criteria
for injection cycles 2 and 3 included clinical justification
for doses of incobotulinumtoxinA ≥600 U (confirmed by a
neurologist or rehabilitation physician), absence of infec-
tion at the planned injection site, absence of severe weak-
ness of the target muscle that would preclude injection of
incobotulinumtoxinA, INR < 1.5, and FEV1 ≥ 60%.
All subjects were required to provide written informed
consent. The subject-reported outcomes, which were
evaluated to address the impact of treatment on subject
QoL, are detailed below.
Assessment of quality of life
Quality of life was assessed as an efficacy variable in the
TOWER study. Subjects completed the three-level ver-
sion of EQ-5D [26, 27] at the injection baseline visit of
each injection cycle, at 4 weeks post-injection ±3 days in
each injection cycle, and at the end-of-cycle-3 visit (end
of study), giving a total of 7 assessments.
Subjects rated their current state of health on a quan-
titative visual analog scale (VAS) from 0 (worst) to 100
(best). For each dimension of the EQ-5D descriptive sys-
tem (Mobility, Self-care, Usual activities, Pain/discomfort
and Anxiety/depression), subjects also selected the state-
ment that best described their health state on that day:
no problems reported (normal condition, score 1); some
problems reported (moderate impairment, score 2); and
extreme problems reported (severe impairment, score 3).
Statistical analysis
As this was an exploratory trial, no formal sample size
calculation was performed. The efficacy analyses are
based on the full analysis set (FAS), which included allsubjects who received ≥1 dose of the study medication.
Variables were analysed by descriptive statistics. Analysis
of EQ-5D scores was performed using observed cases.
Mean changes in EQ-5D VAS score from the study base-
line to 4 weeks post-treatment in each injection cycle were
assessed by the Student’s t-test (two-sided) for paired sam-
ples. Changes in EQ-5D dimension data from each injec-
tion cycle baseline to 4 weeks post-injection were analyzed
using frequency tables. In addition, we describe the fre-
quencies of EQ-5D dimension scores at study baseline
and the end of injection cycle 3.
Results
Subjects and exposure
A total of 155 subjects participated and were treated
in the study between May 2012 and September 2014,
and were included in the FAS (Additional file 1: Fig.
S1). Eighteen (11.6%) subjects discontinued the study,
with three subjects discontinuing after injection in in-
jection cycle 1, 12 subjects after injection in cycle 2,
and three subjects after injection in cycle 3. Details of
the reasons for study discontinuation have been pub-
lished previously [20].
Subject characteristics and baseline demographics are
summarized in Table 1. The subjects had a mean (stand-
ard deviation [SD]) age of 53.7 (13.1) years and the
majority were male (67.1%). Cerebral vascular disorders
were the cause of spasticity for 138 (89.0%) cases, with
85.2% of subjects having cerebral stroke as the cause.
Median time since the diagnosis of the event leading to
spasticity of the right and left body sides was 46.5 and
61.4 months, respectively. At study baseline, the mean
(SD) REPAS score for assessment of muscle tone of the
treated body side was 24.8 (6.7) and the mean (SD) score
for all functional domains of the DAS ranged from 2.6
(0.5) to 2.8 (0.4).
All subjects had spasticity of both the upper and
lower limb. One subject had spasticity of both upper
limbs and two subjects had spasticity of both lower
limbs. The majority of subjects (85.8%) had previously
received treatment with BoNT (type A or B). Median
(range) time since the most recent injection of BoNT
was 4.4 months (2.7–93.9 months). Depression was
reported for 34.8% of subjects and anxiety was reported
for 11.0% of subjects. In total, 43.9 and 20.6% of
subjects were receiving concomitant psychoanaleptics
and psycholeptics, respectively.
Seventy-one (45.8%) subjects were treated on the right
side of the body and 84 (54.2%) subjects were treated on
the left side. Most subjects received the scheduled dose
in each injection cycle (91.0% [141/155] received 400 U
in cycle 1; 90.8% [138/152] received 600 U in cycle 2;
and 82.9% [116/140] received 800 U in cycle 3). A total
of 140 (90.3%) subjects received all three injections.
Table 1 Subject demographics and baseline characteristics (FAS)
Characteristic Subjects
N = 155





Black/African American 4 (2.6)
Other 3 (1.9)
Missing 19 (12.3)
BMI (kg/m2), mean (SD) 27.5 (4.9)
Cause of spasticity, n (%)
Ischemic stroke 87 (56.1)
Hemorrhagic stroke 45 (29.0)
Traumatic brain injury 11 (7.1)
Other cerebral vascular disorders 6 (3.9)
Brain tumor 4 (2.6)
Cerebral palsy 2 (1.3)
Time since diagnosis of event leading to spasticity (months),
median (range)
Left body side; n = 81 61.4 (2.8–428.9)
Right body side; n = 68 46.5 (3.7–372.8)
REPASa score at study baseline, mean (SD) 24.8 (6.7)
DASb score at study baseline, mean (SD)
Principle therapeutic target 2.6 (0.5)
Hygiene 2.6 (0.5)
Dressing 2.6 (0.5)
Limb position 2.6 (0.5)
Pain 2.8 (0.4)
aREPAS score of the treated body side consisting of the sum scores for 13
items, each rated using the Ashworth Scale from 0 to 4, ranging from 0 (no
resistance to passive movement for any of the items) to 52 (limbs rigid to
passive movement for all items)
bDAS score, ranging from 0 (no disability) to 3 (severe disability, normal
activities limited)
BMI body mass index, DAS Disability Assessment Scale, FAS full analysis set,
REPAS Resistance to Passive Movement Scale, SD standard deviation
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EQ-5D VAS
Compared with study baseline, there was an improvement
in mean EQ-5D VAS score 4 weeks post-injection in cycle
1, which was sustained with subsequent injections. The
mean (SD) EQ-5D VAS score improved from 59.9 (18.9)
at the study baseline to 66.7 (17.6) 4 weeks post-injection
in cycle 1, and improved further to 70.5 (16.7) at the end
of cycle 3 (Fig. 1a), corresponding to a mean (95% confi-
dence interval [CI]) change of 10.5 (7.6, 13.4) from study
baseline to the end of cycle 3 (p < 0.0001, Student’s t-test
for paired samples; Fig. 1b). The mean (SD) change in
EQ-5D VAS score from the study baseline to 4 weekspost-treatment was 6.7 (14.1) in cycle 1, 9.6 (16.3) in cycle
2, and 8.6 (17.0) in cycle 3 (p < 0.0001 for all versus study
baseline, Student’s t-test for paired samples).
EQ-5D dimension ratings
Among those subjects who had a change in the rating of
their condition at 4 weeks post-injection, a greater
proportion of subjects had ‘improvement’ than ‘worsen-
ing’ for all dimensions across all injection cycles, with
the exception of Self-care in injection cycle 2 (Table 2).
The proportion of subjects with ‘improvement’ was
≥10% greater than that with ‘worsening’ of their condi-
tion for Mobility in injection cycle 1, Pain/discomfort
for all injection cycles, and Anxiety/depression in in-
jection cycle 1. At 4 weeks post-injection, the majority
of subjects had ‘no change’ in the rating of their
condition within each injection cycle for individual
EQ-5D dimensions (Table 2).
From the study baseline to the end of injection cycle 3,
the proportion of subjects with improvements in EQ-5D
ratings was greater than the proportion of subjects with
worsening of ratings for all dimensions: Mobility, 11.4%
versus 2.9%; Self-care, 21.4% versus 7.1%; Usual activ-
ities, 24.3% versus 5.0%; Pain/discomfort, 30.7% versus
9.3%; Anxiety/depression, 25.0% versus 9.3% (Fig. 2).
The proportions of subjects rating their condition as
‘normal’, ‘moderate impairment’, or ‘severe impairment’
for each dimension at study baseline and the end of
injection cycle 3 are shown in Table 3.
Across all dimensions, compared with study baseline,
there was an increase in the proportion of subjects rat-
ing their condition as ‘normal’ at the end of injection
cycle 3. This improvement was > 10% for Pain/discom-
fort (34.2% at baseline to 51.4% at end of injection cycle
3) and Anxiety/depression (46.5% at baseline to 58.6% at
end of injection cycle 3). The proportion of subjects with
‘severe impairment’ was reduced by ≥46% for all EQ-5D
dimensions at the end of injection cycle 3 compared
with study baseline; however, this condition rating
applied to a small proportion of subjects overall (≤ 20%
at baseline for all dimensions; Table 3 and Fig. 3).
Discussion
TOWER was the first prospective clinical study to dem-
onstrate that dose escalation with total body doses of
incobotulinumtoxinA up to 800 U enables treatment in
a greater number of muscles/spasticity patterns, without
compromising safety or tolerability [20]. Consistent with
the observed improvements in muscle tone and better
goal attainment associated with dose escalation from
400 to 800 U of incobotulinumtoxinA presented previ-
ously [20], we demonstrated the beneficial effects of
incobotulinumtoxinA on QoL among this study popula-
tion. There were sustained improvements in QoL across
Fig. 1 a Mean (SD), and b mean (95% CI) change in EQ-5D VAS scores (FAS). a) Time points: at injection cycle baseline and 4 weeks post-injection
in each injection cycle and at the end of injection cycle 3. b) Time points: from the study baseline to 4 weeks post-injection in each injection
cycle and to the end of injection cycle 3. Positive values indicate improvement. *p < 0.0001 compared with the study baseline visit in injection
cycle 1, Student’s t-test for paired samples. CI, confidence interval; EQ-5D, EuroQol 5-dimensions questionnaire, three-level; FAS, full analysis set; SD,
standard deviation; VAS, visual analog scale
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self-assessed health status (EQ-5D VAS) across injection
cycles. Among those subjects who had a change in the
rating of their condition, at the end of injection cycle 3 a
greater proportion of subjects had improvement of rat-
ings from injection cycle baseline than worsening of rat-
ings for all dimensions of the EQ-5D. Similarly, the
proportion of subjects with a rating of ‘normal condition’
in each of the five EQ-5D dimensions was greater and
the proportion with ‘severe impairment’ to QoL was
lower at the end of injection cycle 3, compared with
ratings at study baseline. Of note, there was a ≥ 46%
decrease in the proportion of subjects with ‘severe im-
pairment’ for all five EQ-5D dimensions by the end of
injection cycle 3. However, the numbers of subjects with
ratings of ‘severe impairment’ were low, particularly for
the Mobility dimension. The factors that may identifywhich subjects will experience QoL improvements that
can be measured using EQ-5D are currently unknown.
Furthermore, as this was an exploratory trial without a
parallel fixed-dose comparator arm or placebo control,
these QoL results are descriptive; randomized controlled
studies are required to confirm the findings.
Few studies have investigated the effect of BoNT-A treat-
ment on subjects’ QoL [1, 3]. In a non-interventional study,
incobotulinumtoxinA in combination with conventional
therapy (oral antispasticity medication, physiotherapy, and
occupational therapy) significantly improved QoL (assessed
by 12-Item Short Form Health Survey score) compared
with baseline during 1-year treatment of post-stroke
upper-limb spasticity [12]. The TOWER study is, to our
knowledge, the first to provide some evidence of an
improvement in QoL using escalating doses of BoNT-A
for the simultaneous treatment of upper- and lower-limb
Table 2 Change in EQ-5D dimensions from injection cycle baseline to 4 weeks post-injection (FAS)
Dimension Injection cycle N Nobs Improvement, n (%) No change, n (%) Worsening, n (%)
Mobility 1 155 155 18 (11.6) 135 (87.1) 2 (1.3)
2 152 149 11 (7.2) 136 (89.5) 2 (1.3)
3 140 138 6 (4.3) 128 (91.4) 4 (2.9)
Self-care 1 155 155 19 (12.3) 123 (79.4) 13 (8.4)
2 152 148 7 (4.6) 127 (83.6) 14 (9.2)
3 140 138 11 (7.9) 121 (86.4) 6 (4.3)
Usual activities 1 155 155 20 (12.9) 126 (81.3) 9 (5.8)
2 152 148 18 (11.8) 116 (76.3) 14 (9.2)
3 140 138 8 (5.7) 126 (90.0) 4 (2.9)
Pain/discomfort 1 155 155 40 (25.8) 105 (67.7) 10 (6.5)
2 152 149 32 (21.1) 105 (69.1) 12 (7.9)
3 140 138 29 (20.7) 102 (72.9) 7 (5.0)
Anxiety/depression 1 155 155 27 (17.4) 119 (76.8) 9 (5.8)
2 152 149 18 (11.8) 121 (79.6) 10 (6.6)
3 140 138 18 (12.9) 111 (79.3) 9 (6.4)
EQ-5D EuroQol 5-dimensions questionnaire, three-level, FAS full analysis set, N number of subjects treated, Nobs number of observed cases
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bility to increase the dose per muscle within the defined
dose range, and enabled the treatment of more muscles
and clinical patterns according to the needs and treatment
goals of the individual subject [20], and this may have con-
tributed to improvement in QoL.
The EQ-5D has previously been validated in subjects
following stroke [28], who form the largest proportion of
the TOWER study population. Differences in EQ-5D
scores between stroke survivors with and withoutFig. 2 Subjects with improvement or worsening of EQ-5D ratings in all dim
cycle 3 (N = 138). EQ-5D, EuroQol 5-dimensions questionnaire, three-level; Fspasticity met the minimal clinically important differ-
ences previously established for other validated diseases,
potentially supporting the use of EQ-5D as a measure of
QoL in this population [4]. However, the use of EQ-5D
may be considered a limitation of this study, since it is
not validated for use in spasticity.
The three-level EQ-5D, which was the only version
available at the outset of this study, may lack the sen-
sitivity required to capture incremental but meaning-
ful changes in QoL in these subjects. For example, aensions (FAS). Time points: from study baseline to the end of injection
AS, full analysis set; n, number of observed cases
Table 3 EQ-5D dimension score frequency at study baseline and end of cycle 3 (FAS)







Mobility Baseline 155 155 12 (7.7) 139 (89.7) 4 (2.6)
End of injection cycle 3 140 137 23 (16.4) 112 (80.0) 2 (1.4)
Self-care Baseline 155 155 30 (19.4) 96 (61.9) 29 (18.7)
End of injection cycle 3 140 137 33 (23.6) 93 (66.4) 11 (7.9)
Usual activities Baseline 155 155 11 (7.1) 113 (72.9) 31 (20.0)
End of injection cycle 3 140 137 22 (15.7) 103 (73.6) 12 (8.6)
Pain/discomfort Baseline 155 155 53 (34.2) 85 (54.8) 17 (11.0)
End of injection cycle 3 140 137 72 (51.4) 60 (42.9) 5 (3.6)
Anxiety/depression Baseline 155 155 72 (46.5) 69 (44.5) 14 (9.0)
End of injection cycle 3 140 137 82 (58.6) 53 (37.9) 2 (1.4)
EQ-5D EuroQol 5-dimensions questionnaire, three-level, FAS full analysis set, N number of subjects treated, Nobs number of observed cases
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used the EQ-5D questionnaire to measure QoL in
subjects with upper-limb spasticity due to stroke did
not demonstrate any significant improvement in the
Mobility, Self-care, or Usual activities dimensions up to
12 months post-treatment [29]. Although significant
improvements were observed at some time points for
the Pain/discomfort and Anxiety/depression dimen-
sions, the magnitude of these changes was negligible
and the clinical significance was unclear [29]. Pain/dis-
comfort may be most successfully alleviated with
high-dose treatment. Therefore, it may be noteworthy
that Pain/discomfort and Anxiety/depression were also
the dimensions for which we observed the highest fre-
quency of subjects with improvement and the greatestFig. 3 ‘Severe impairment’ of QoL at study baseline and end of cycle 3 (FA
analysis set; n, number of observed cases; QoL, quality of lifeproportion of subjects rating their condition as ‘normal’ at
the end of injection cycle 3. While these findings might
suggest that treatment with BoNT-A has a positive impact
on these aspects of QoL, it is also possible that these are
the dimensions most likely to be influenced by the clinical
trial environment where subjects are receiving highly
structured spasticity management from a specialist team.
Notably, the comparatively low proportion of subjects
who experienced an improvement in Mobility, Self-care,
and Usual activities is likely to reflect a high degree of
underlying motor deficits in this chronic population, as
demonstrated by the high REPAS and DAS scores at study
baseline. This suggests that subjects experiencing painful
spasticity, but with sufficient underlying motor function,
may experience greater QoL improvements with high-doseS). EQ-5D, EuroQol 5-dimensions questionnaire, three-level; FAS, full
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cant functional impairment.
Interestingly, the greatest proportion of subjects with
improvements in all EQ-5D dimensions occurred follow-
ing treatment with 400 U in the first injection cycle, with
sustained improvement in subsequent injection cycles,
suggesting a ceiling effect, which has also been observed
in previous studies using the three-level EQ-5D [30].
Future studies of QoL in subjects with spasticity may
benefit from use of the five-level EQ-5D [31], which in-
corporates additional terms to describe health status and
is expected to offer better sensitivity and discriminatory
capacity than the EQ-5D [31, 32]. Novel tools, such as
the Spasticity-Related Quality-of-Life Tool (SQoL-6D),
are in development specifically for spasticity and may
also be of value for future research once validated [33].
Given the limited assessment tools available, it is unsur-
prising that there is a paucity of data on QoL in subjects
with chronic spasticity. In particular, the lack of normative
QoL data for subjects with upper- and lower-limb spasti-
city is a major limitation when interpreting changes in
QoL as a result of BoNT-A intervention. It is intended
that the results reported here will serve as a valuable start-
ing point for further research in this field.
Conclusions
The safety and efficacy of BoNT-A formulations for the
treatment of upper- and lower-limb spasticity are well
established, and these formulations form a key component
of the multidisciplinary management of this condition
[9–19, 34, 35]. A subject-centered approach to manage-
ment of spasticity, as shown for incobotulinumtoxinA, is
important to help subjects achieve their individual goals
and also improve their QoL [6]. Consistent with previous
reports [21, 36–38], results of the TOWER study showed
that treatment with total body doses of incobotulinumtoxinA
up to 800U is well tolerated, and no new safety concerns
were identified for higher cumulative doses [20]. Using
higher doses of incobotulinumtoxinA enables simultaneous
treatment of more clinical patterns of upper- and lower-limb
spasticity that is very likely to also contribute to improve-
ment in multiple aspects of subjects’ QoL, supporting its
potential role in the rehabilitation of subjects with multifocal
upper- and lower-limb spasticity.
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